Monarc-M Powder For Solution For Injection 1250iu Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Monarc-M: Powder for solution for injection (1250IU)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png


What is this Medicine?

ANTIHEMOPHILIC FACTOR (AHF or FACTOR VIII) (an tee hee moe FIL ik fak tir) is used to prevent or control bleeding in patients with hemophilia A. This medicine is also used in these patients during surgery. Some products are used to treat von Willebrand's disease.

In-Depth Information

Monarc-M Powder for Injection (801-1700units)

NDC: 009441303
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)




FDA approved for the following conditions:
Surgical Bleeding Prophylaxis, Bleeding Prophylaxis

Sometimes used for but not FDA approved for the following conditions:
Hemophilia A, Hemorrhage

Storage Information
Store in refrigerator (36 to 46 degrees F) or at room temperature, not to exceed 86 degrees F
Protect from freezing
Monarc-M Powder for Injection (801-1700units)

Reported Side Effects for Monarc-M Powder for Injection (801-1700units)

Antibody Formation Incidence:
0.5-30.0%*
Severity: MODERATE
Onset: DELAYED
Rapid Heart Rate Incidence:
0.5%*
Severity: MODERATE
Onset: RAPID
Lightheadedness Incidence:
0.5-2.2%*
Severity: MILD
Onset: EARLY
Infection Incidence:
0.5-9.0%*
Severity: MILD
Onset: DELAYED
Pale Skin Incidence:
0.5%*
Severity: MILD
Onset: EARLY
Upset Stomach Incidence:
0.5-13.0%*
Severity: MILD
Onset: EARLY
Chest Pain Incidence:
0.5%*
Severity: MODERATE
Onset: EARLY
Cough Incidence:
0.5-19.0%*
Severity: MILD
Onset: DELAYED
Tired Incidence:
>0.5%*
Severity: MILD
Onset: EARLY
High Bilirubin Level Incidence:
0.5%*
Severity: MODERATE
Onset: DELAYED
Excessive Sweating Incidence:
0.5%*
Severity: MILD
Onset: DELAYED
Low Blood Pressure Incidence:
0.5%*
Severity: MODERATE
Onset: RAPID
Muscle Pain Incidence:
0.5%*
Severity: MILD
Onset: EARLY
Stomach Pain Incidence:
0.5%*
Severity: MILD
Onset: EARLY
Shaking Incidence:
0.5%*
Severity: MILD
Onset: EARLY
Metallic Taste Incidence:
0.8-1.4%*
Severity: MILD
Onset: EARLY
Headache Incidence:
0.8-26.0%*
Severity: MILD
Onset: EARLY
Decreased Appetite Incidence:
0.9%*
Severity: MILD
Onset: DELAYED
Drowsiness Incidence:
0.9%*
Severity: MILD
Onset: EARLY
Flushing Incidence:
1.0%*
Severity: MILD
Onset: RAPID
Weakness Incidence:
1.4-7.0%*
Severity: MILD
Onset: DELAYED
Fluid Retention Incidence:
1.4%*
Severity: MODERATE
Onset: DELAYED
Elevated Hepatic Enzymes Incidence:
1.4%*
Severity: MODERATE
Onset: DELAYED
Vomiting Incidence:
1.5-12.0%*
Severity: MILD
Onset: EARLY
Irritated Blood Vessels Incidence:
1.5%*
Severity: MODERATE
Onset: RAPID
Peripheral Vasodilation Incidence:
2.3%*
Severity: MODERATE
Onset: RAPID
Postural Low Blood Pressure Incidence:
2.6%*
Severity: MODERATE
Onset: DELAYED
Shortness Of Breath Incidence:
2.8%*
Severity: MODERATE
Onset: EARLY
Paresthesias Incidence:
>2.8%*
Severity: MILD
Onset: DELAYED
Loose Stools Incidence:
5.0-8.0%*
Severity: MILD
Onset: EARLY
Runny Nose Incidence:
5.0%*
Severity: MILD
Onset: EARLY
Stuffy Nose Incidence:
8.0%*
Severity: MILD
Onset: EARLY
Joint Pain Incidence:
12.0-25.0%*
Severity: MILD
Onset: DELAYED
Sore Throat Incidence:
17.0%*
Severity: MILD
Onset: DELAYED
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Monarc-M

Be the first to share your experience!

We want to help our customers stay educated about the medications they are taking. Submit your own observations and experiences to benefit others.

Average Scores
Easy to Take 
0 / 5
0 / 5
Works as Intended 
0 / 5
0 / 5
Tolerable 
0 / 5
0 / 5